港股异动 | 信达生物涨超4% 携手礼来制药公布ORIENT-12研究结果
智通财经APP获悉，信达生物 (HK:1801)和礼来制药共同宣布，在2020年欧洲肿瘤内科学会(ESMO)线上年会以口头报告形式公布ORIENT-12研究结果。ORIENT-12是全球首个PD-1单抗联合吉西他滨和铂类(GP方案)用于晚期鳞状非小细胞肺癌(sqNSCLC)一线治疗的随机、双盲、III期对照临床研究。
截至发稿，信达生物涨4.23%，报65.3港元，成交额1.33亿港元。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
If you like, reward to support.
Hot
No comment on record. Start new comment.